Pujet J C, Homberg J C, Decroix G
Br Med J. 1974 May 25;2(5916):415-8. doi: 10.1136/bmj.2.5916.415.
Five out of 200 patients taking rifampicin 900 mg twice weekly and three out of 91 patients taking rifampicin who attended an immunology clinic developed intolerance to the drug. Antibodies to rifampicin, which were found in most cases, decreased steadily after the end of treatment but were detectable for up to 16 months. The dose of rifampicin and the blood levels are predominating factors in the occurrence of reactions. Thus the dose should be reduced in patients in whom rifampicin blood levels rise abnormally. When it is important to continue rifampicin treatment despite intolerance antibody titres within 24 hours after administration of the drug must be measured to find when they are lowest, which determines the "unreactive period," and when a further dose may be safely given.
200名每周两次服用900毫克利福平的患者中有5人，以及91名前往免疫诊所就诊的服用利福平的患者中有3人出现了药物不耐受情况。在大多数病例中发现的利福平抗体，在治疗结束后稳步下降，但在长达16个月的时间内仍可检测到。利福平的剂量和血药浓度是反应发生的主要因素。因此，利福平血药浓度异常升高的患者应减少剂量。当尽管存在不耐受情况但仍有必要继续使用利福平治疗时，必须在给药后24小时内测量抗体滴度，以确定其何时最低，即“无反应期”，以及何时可以安全地给予下一剂药物。
